第16回千葉カルシウム代謝研究会

Gene ontology term enrichments for RNA-Seq data from differentiated TSC2 deletion cell lines and microarray data of patient SEGAs (related to Fig. 2f). (XLSX 27.7 kb

Additional file 8: Table S5. of Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model

Gene set enrichment analysis of ribosome profiling data (related to Fig. 3d). (XLSX 11.1 kb

Additional file 9: Table S6. of Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model

Gene ontology term enrichments for ribosome profiling data (related to Fig. 3f). (XLSX 11 kb

Additional file 11: Table S8. of Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model

Gene sets and associated genes that show after mTOR treatment a reversal of the change in expression detected in untreated TSC2 deletion cells (related to Fig. 4b). (XLSX 25.8 kb

Additional file 10: Table S7. of Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model

RNA-Seq and ribosome profiling data of differentiated TSC2 wild-type and homozygous deletion cell lines treated with mTOR inhibitors (related to Fig. 4). (XLSB 7.52 mb

Additional file 2: Figure S2. of Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model

Loss of TSC2 triggers expression changes related to inflammatory response, metabolism, and neuronal function. (PDF 1.15 mb

Additional file 1: Figure S1. of Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model

Deregulated expression of neuronal and glial markers in the absence of TSC2. (PDF 2.73 mb